Keyphrases
Non-small Cell Lung Cancer (NSCLC)
100%
Melanoma
100%
OX40
100%
Advanced Solid Tumors
100%
Antibody Combinations
100%
Agonistic Antibody
100%
4-1BB
100%
First-in-human Study
100%
Utomilumab
100%
Dose Escalation
66%
Dose Expansion
66%
Stable Disease
50%
Antitumor Activity
33%
Adverse Events
33%
Response Evaluation Criteria in Solid Tumors (RECIST)
33%
Partial Response
33%
Immunophenotyping
33%
Programmed Death-ligand 1 (PD-L1)
33%
Disease Control Rate
33%
Pharmacodynamic Interactions
33%
Monoclonal Antibody
16%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
16%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
16%
Cervical Cancer
16%
Bladder
16%
Tumor Biopsy
16%
Safety Activity
16%
Dose Effect
16%
Dose Level
16%
Immune Response
16%
Agonistic
16%
Gastric Cancer
16%
Treatment-related Adverse Events
16%
Whole Blood
16%
Tolerability
16%
Area under the Concentration-time Curve
16%
Pharmacokinetics-pharmacodynamics (PK-PD)
16%
Median Range
16%
Trial Registration
16%
Humanized
16%
Anti-cytotoxic
16%
National Cancer Institute Common Terminology Criteria for Adverse Events
16%
Pharmacokinetic Effects
16%
Whole Blood Sample
16%
First-in-human
16%
IgG2
16%
Pharmacology, Toxicology and Pharmaceutical Science
Solid Malignant Neoplasm
100%
Non Small Cell Lung Cancer
100%
Melanoma
100%
Human Study
100%
Utomilumab
100%
Diseases
83%
Adverse Event
66%
Antitumor Activity
33%
Pharmacodynamics
33%
Neoplasm
16%
Head and Neck Squamous Cell Carcinoma
16%
Malignant Neoplasm
16%
Abdominal Cancer
16%
Monoclonal Antibody
16%
Death Receptor
16%
Uterine Cervix Cancer
16%
Pharmacokinetic
16%
Tolerability
16%
Programmed Death 1 Ligand 1
16%
Cytotoxic T Lymphocyte Antigen 4
16%
Immunoglobulin G2
16%
Immunology and Microbiology
Utomilumab
100%
Antineoplastic Activity
33%
Pharmacodynamics
33%
Monoclonal Antibody
16%
CTLA-4
16%
Squamous Cell
16%
Neck
16%
Death Receptor
16%
Immunity
16%
Pharmacokinetic
16%
Programmed Death 1 Ligand 1
16%
Nomenclature
16%
Immunoglobulin G2
16%